Oramed Pharmaceuticals (NASDAQ:ORMP) Announces Quarterly Earnings Results, Misses Expectations By $0.52 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP) announced its earnings results on Monday. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.52), Zacks reports.

Oramed Pharmaceuticals Stock Performance

Shares of Oramed Pharmaceuticals stock opened at $4.20 on Tuesday. Oramed Pharmaceuticals has a one year low of $1.98 and a one year high of $5.19. The company has a market cap of $174.72 million, a PE ratio of 1.62 and a beta of 1.22. The business has a 50-day simple moving average of $4.13 and a 200-day simple moving average of $3.82.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock has a consensus rating of “Hold”.

Insider Activity at Oramed Pharmaceuticals

In other Oramed Pharmaceuticals news, COO Joshua Hexter sold 137,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.46, for a total value of $611,020.00. Following the sale, the chief operating officer directly owned 1,023,384 shares of the company’s stock, valued at approximately $4,564,292.64. This represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Avraham Gabay sold 73,360 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total transaction of $330,853.60. Following the completion of the sale, the chief financial officer owned 671,785 shares in the company, valued at $3,029,750.35. The trade was a 9.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 20.77% of the stock is owned by company insiders.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. XTX Topco Ltd grew its position in Oramed Pharmaceuticals by 59.9% during the 4th quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 14,297 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth about $119,000. HRT Financial LP purchased a new position in shares of Oramed Pharmaceuticals during the fourth quarter worth about $131,000. Jane Street Group LLC grew its holdings in shares of Oramed Pharmaceuticals by 35.3% during the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock worth $144,000 after buying an additional 17,510 shares during the last quarter. Finally, Squarepoint Ops LLC increased its position in Oramed Pharmaceuticals by 95.1% in the 4th quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 28,406 shares during the period. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.